Who we are

A cooperative oncology group that designs and administers cancer clinical trials

The Canadian Cancer Trials Group (CCTG) is a cooperative oncology group that designs and administers clinical trials in cancer therapy, supportive care and prevention across Canada. We support a collaborative network of researchers, physicians, scientists and statisticians internationally recognized for finding the treatments that give people with cancer longer, better quality lives.

Created in 1980, the group has run trials resulting in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer. The network is made of more than 85 member institutions, comprising over 2000 Canadian investigators working with 4200 clinical trial staff and has facilitated over 500 trials in more than 40 countries. Most importantly are the 1500-3000 patient volunteers per year who participate in our trials in order to potentially receive better treatments that could also benefit others in the future.

CCTG’s Central Operations and Statistics Office is located in the Cancer Research Institute at Queen’s University, with in-house faculty researchers that include clinician scientists, researchers in community health and epidemiology, and biostatisticians.

The group is proud to be one of the national programmes of the Canadian Cancer Society (CCS), the only non-American partner of the US National Clinical Trials Network and collaborators with research cooperative groups around the world. These international partnerships are central to the success of their cancer clinical trials and crucial to the advancement of the cancer research agenda in Canada.

Our mission

To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

Find out more:

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater receives inaugural Canadian Cancer Society Lifetime Contribution Prize

Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).

More >>
 
Dr. Elizabeth Eisenhauer by Bernard Clark

Dr. Elizabeth Eisenhauer presented with 2021 Canada Gairdner Wightman Award

Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.

More >>
 
Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Dr. Cheung and Dr. Hay receive bridge funding - CIHR Fall 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received an additional $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Fall 2020 competition matching funds awarded in the spring from this program designed to capture and support ideas with the greatest potential to advance health-related knowledge in Canada. 

More >>
 

CIHR funding award announced for rare cancer study

Congratulations to Dr. Tricia Cottrell, a CCTG Senior Investigator, has been awarded $872,86 to support the IND227 study from the Canadian Institutes of Health Research (CIHR) Fall Project Competition.

Malignant Pleural Mesothelioma is rare and deadly form of cancer. Patients do not respond well to the current standard of care. However, there have been some positive results using immunotherapy.  Immunotherapy is a new way of treating cancer that “turns on” an individual’s anticancer immune response.

More >>